Establishment of immunity against Epstein-Barr virus infection in a patient with CHARGE/complete DiGeorge syndrome after peripheral blood lymphocyte transfusion

Pediatr Transplant. 2019 Jun;23(4):e13424. doi: 10.1111/petr.13424. Epub 2019 Apr 29.

Abstract

CHARGE syndrome is a rare congenital malformation syndrome which may share symptoms with DiGeorge syndrome. Complete DiGeorge syndrome (cDGS) is a severe form of DiGeorge syndrome, characterized by a CD3+ T-cell count of <50/mm3 due to athymia, and is fatal without immunologic intervention. We performed peripheral blood lymphocyte transfusion (PBLT) from an HLA-identical sibling without pretransplant conditioning in a CHARGE/cDGS patient with a novel CHD7 splice site mutation. Cyclosporine and short-term methotrexate were used for graft versus host disease (GVHD) prophylaxis, and neither acute nor chronic GVHD was observed. After PBLT, T-cell proliferative response to phytohemagglutinin and concanavalin A recovered, and intractable diarrhea improved. EBV infection, evidenced by a gradual increase in the viral genome copy number to a maximum of 2861 copies/μgDNA on day 42 after PBLT, resolved spontaneously. HLA A2402 restricted, EBV-specific CTLs were detected from peripheral blood on day 148, and EBV seroconversion was observed on day 181. Thus, EBV-specific immunity was successfully established by PBLT. Our results indicate that PBLT is a simple and effective therapy to reconstitute immune systems in CHARGE/DiGeorge syndrome.

Keywords: CHARGE syndrome; CHD7 mutation; DiGeorge syndrome; Epstein-Barr virus; immune reconstitution; peripheral blood lymphocyte transfusion.

Publication types

  • Case Reports

MeSH terms

  • CD3 Complex / metabolism
  • CHARGE Syndrome / therapy*
  • Cell Proliferation
  • Concanavalin A / pharmacology
  • Cyclosporine / administration & dosage
  • DiGeorge Syndrome / complications*
  • DiGeorge Syndrome / immunology*
  • Diarrhea / therapy
  • Epstein-Barr Virus Infections / immunology
  • Epstein-Barr Virus Infections / prevention & control*
  • Fatal Outcome
  • Graft vs Host Disease
  • HLA Antigens / chemistry
  • Herpesvirus 4, Human / genetics
  • Humans
  • Infant, Newborn
  • Lymphocyte Transfusion*
  • Male
  • Methotrexate / administration & dosage
  • Mutation
  • Phenotype
  • Phytohemagglutinins / chemistry
  • Siblings
  • T-Lymphocytes / cytology

Substances

  • CD3 Complex
  • HLA Antigens
  • Phytohemagglutinins
  • Concanavalin A
  • Cyclosporine
  • Methotrexate